Two ways to improve

diabetes care
NycoCard HbA1c and
NycoCard U-Albumin

3 minutes test time

Test procedure

NycoCard HbA1c
Determines the quality of metabolic control
The importance of good metabolic control

1. Add 5 L whole blood to the

test tube with reagent. Mix well.
Incubate for 2 minutes.

Several studies have shown the importance of good metabolic

control in preventing and slowing the progression of diabetic late
complications - for persons with Type I (DCCT study1) and Type II
(UKPDS2,3,4,5) diabetes. Measurement of glycated haemoglobin has
proven to be an important tool in determining the quality of the
metabolic control.

Time-saving for you and your patients

2. Mix again. Apply 25 L reaction

mixture to the Test Device.

NycoCard HbA1c is rapid and provides an accurate HbA1c result

within 3 minutes during the patient consultation making a revisit
to alter the treatment regime no longer necessary.

Standardisation

3. Add 25 L Washing Solution.

The International Federation of Clinical Chemistry (IFCC) has

established a working group on glycohaemoglobin standardisation.
This will be based on HbA1c, as it is the easiest component to
define. Methods that measure total haemoglobin, such as affinity
methods, can also be standardised against HbA1c, as their
respective values correlate well6.
NycoCard HbA1c is standardised according to the
recommendations of the ERL laboratory (European Reference
laboratory) at DCCT-level and is certified in accordance with the
ERL Check-Up Protocol.

Characteristics
4. Read the result within 5 minutes
using the NycoCard READER II.

Measuring range: 3-18% HbA1c

Reference range: 4.5-6.3% HbA1c
Sample material: 5 L whole blood
Test result within 3 minutes
Precision:

A coefficient of variation (CV) below 5%

both within and between run.

No interference of haemoglobin variants or derivatives7,8,9

Test procedure

NycoCard U-Albumin
Pin-points patients at risk
Why measure urinary albumin concentrations?

1. Add 50 L urine to a test tube

with Dilution Liquid. Mix well.

Diabetic nephropathy is a frequent and serious secondary

complication of diabetes mellitus, leading to increased morbidity
and mortality, and to impaired quality of life in persons
affected10,11. Early detection of the disease, at the stage of microalbuminuria, is important for its outcome and progression.
If appropriate measures are taken, microalbuminuria can be halted
or even reversed12.
Microalbuminuria is defined as a persistent elevation of the
urinary albumin excretion to 20-200 g/min or 20-200 mg/L
when using early morning urine10.

2. Apply 50 L diluted urine to

the Test Device.

3. Apply 50 L Conjugate to
the Test Device.

Studies have demonstrated that microalbuminuria independently

predicts cardiovascular morbidity and all-cause mortality in
essential hypertension. Monitoring of microalbuminuria is worthwhile in order to monitor the effect of anti-hypertensive treatment
on target-organ damage14.
Low-protein diets, lowering blood pressure and the use of antihypertensive therapy have all been reported to have a positive
effect on decreasing the urinary albumin excretion11,13. The DCCT
Research Group has shown the importance of strict glycaemic
control in preventing microalbuminuria1.

NycoCard U-Albumin is simple, quick and convenient within

only 3 minutes a quantitative test result is obtained using the
NycoCard READER II.

Characteristics
4. Apply 50 L Washing Solution
to the Test Device.

Measuring range: 5-200 mg/L albumin

Sample material: 50 L urine

5. Read the test result within

5 minutes using NycoCard
READER II.

Test principle:

Solid phase, sandwich-format, immunometric

assay using a gold-antibody conjugate.

Precision:

In controlled laboratory testing, a coefficient

of variation (CV) of 5-8% is usually obtained.

Availability
NycoCard U-Albumin, 24 tests
NycoCard U-Albumin Control, 2 x 1 x 1.0 mL
NycoCard HbA1c, 24 tests
NycoCard HbA1c Control, 2 x 0.4 mL
NycoCard READER II kit

NycoCard READER II
One instument, four tests

C-reactive protein
HbA1c
Microalbumin
D-Dimer

8) Clinical Chemistry 39(8):1717-1723, 1993 (300)

9) Clinical Chemistry 29(3):543-545, 1983 (1410)
10) Exp Clin Endocr & Diab 107(4):244-251, 1999 (5390)
11) Ann Med 29:439-445, 1997 (2050)
12) Diabetes Care 21(7):1076-1079, 1998 (5060)
13) New Engl J Med 341(15):1127-1133, 1999 (5560)
14) J Hypertension 14 (Suppl 2):S89-S94, 1996 (1630)

signatur.no

References
1) New Engl J Med 329:977-986, 1993 (340)
2) Lancet 352:837-853, 1998 (2210)
3) Lancet 854-865, 1998 (2220)
4) BMJ 317:703-713, 1998 (2230)
5) BMJ 317:713-720, 1998 (2240)
6) JIFCC 9(2):62-68, 1996 (760)
7) Clinical Chemistry 28(10):2088-2094, 1982 (1400)

Axis-Shield PoC AS
P.O. Box 6863 Rodelkka
N-0504 Oslo, Norway
Telephone +47 22 04 20 00
Fax +47 22 04 20 01
www.axis-shield-poc.com

Mat.nr. 1112714. May 2004

1100296
1114358
1042184
1113022
1113117